February 21, 2020
Amniox Appoints New Vice President of Sales
Brandon Caraway joins organization to help build and lead a world-class sales team
Miami, FL – February 22, 2020– Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the expansion of their Leadership Team with the appointment of Brandon Caraway to the position of Vice President of Sales. In this role, Brandon will oversee all sales operations for the Amniox pipeline of products for surgical, wound care, and other indications.
Brandon will be responsible for the development and execution of business plans for achieving Amniox revenue goals, driving consistent business growth, and developing and managing the Amniox sales team.
“Brandon brings a significant amount of sales and leadership experience to Amniox to help us further develop into THE leader in regenerative medicine,” said Tom Williamson, Chief Commercial Officer. “Brandon’s talent lies in being able to quickly identify ways to align people with their strengths and optimize relationship building. His proven track record as a five-time President’s Club Winner at Entellus Medical substantiates his success as a world-class sales performer and leader. We know that he will do the same for the Amniox sales team.”
Brandon has hired, trained, and developed over 50 top-producing sales representatives and regional managers at Entellus Medical – now a part of Stryker Corporation – and served as principal and director of Houston Laser & Chemical Supply. Brandon earned his Bachelor of Science degree in Economics from the University of Houston and his Master of Business Administration from the University of Houston/Victoria.
About Amniox Medical, Inc.
Amniox Medical, Inc., a TissueTech, Inc. company, is a leader in the clinical application of human birth tissue-based products (amniotic membrane & umbilical cord) processed using TissueTech’s proprietary CryoTek® cryopreserved technology. Established in 2011, Amniox serves an unmet need for better surgical and therapeutic outcomes for chronic and complex wounds, orthopedics, sports medicine, spine, urology, gynecology, plastics, and general surgery. Connect with Amniox on our Website, Facebook, LinkedIn and Twitter.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 360 peer-reviewed studies supporting its platform technology. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at https://biotissue.com/.